Literature DB >> 22694290

Calcium channels and prostate cancer.

George Shapovalov1, Roman Skryma, Natalia Prevarskaya.   

Abstract

Calcium channels significantly contribute to many cellular processes, including such critical ones as proliferation, differentiation, and apoptosis. In prostate cancer, the influence of calcium channels has been known for over 30 years, with the first observations that calcium channel blockers affect the progression of cancer towards more aggressive phase. Later research identified additional classes of channel proteins having an important regulatory role and affecting malignant transformation. This review discusses the accumulated scientific knowledge focused on calcium channel involvement in regulation of cell fate in prostate tissues as well as recent developments in patents targeted at prostate cancer treatments and involving calcium channel modulators.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 22694290     DOI: 10.2174/15748928130103

Source DB:  PubMed          Journal:  Recent Pat Anticancer Drug Discov        ISSN: 1574-8928            Impact factor:   4.169


  14 in total

Review 1.  The calcium-cancer signalling nexus.

Authors:  Gregory R Monteith; Natalia Prevarskaya; Sarah J Roberts-Thomson
Journal:  Nat Rev Cancer       Date:  2017-04-07       Impact factor: 60.716

2.  Calcium Channel Blocker Use and Risk of Prostate Cancer by TMPRSS2:ERG Gene Fusion Status.

Authors:  Milan S Geybels; Karen D McCloskey; Ian G Mills; Janet L Stanford
Journal:  Prostate       Date:  2016-10-18       Impact factor: 4.104

3.  Resveratrol activates autophagic cell death in prostate cancer cells via downregulation of STIM1 and the mTOR pathway.

Authors:  Senthil Selvaraj; Yuyang Sun; Pramod Sukumaran; Brij B Singh
Journal:  Mol Carcinog       Date:  2015-04-27       Impact factor: 4.784

Review 4.  Genetic mutations in the treatment of anaplastic thyroid cancer: a systematic review.

Authors:  Anna Guerra; Vincenzo Di Crescenzo; Alfredo Garzi; Mariapia Cinelli; Chiara Carlomagno; Massimo Tonacchera; Pio Zeppa; Mario Vitale
Journal:  BMC Surg       Date:  2013-10-08       Impact factor: 2.102

5.  TRP channel-associated factors are a novel protein family that regulates TRPM8 trafficking and activity.

Authors:  Dimitra Gkika; Loic Lemonnier; George Shapovalov; Dmitri Gordienko; Céline Poux; Michela Bernardini; Alexandre Bokhobza; Gabriel Bidaux; Cindy Degerny; Kathye Verreman; Basma Guarmit; Mohamed Benahmed; Yvan de Launoit; Rene J M Bindels; Alessandra Fiorio Pla; Natalia Prevarskaya
Journal:  J Cell Biol       Date:  2015-01-05       Impact factor: 10.539

6.  ICRAC controls the rapid androgen response in human primary prostate epithelial cells and is altered in prostate cancer.

Authors:  Christian Holzmann; Tatiana Kilch; Sven Kappel; Andrea Armbrüster; Volker Jung; Michael Stöckle; Ivan Bogeski; Eva C Schwarz; Christine Peinelt
Journal:  Oncotarget       Date:  2013-11

Review 7.  Glottic-Subglottic adenoid cystic carcinoma. A case report and review of the literature.

Authors:  Domenico Testa; Germano Guerra; Giovanni Conzo; Michele Nunziata; Gioacchino D'Errico; Maria Siano; Gennaro Ilardi; Mario Vitale; Francesco Riccitiello; Gaetano Motta
Journal:  BMC Surg       Date:  2013-10-08       Impact factor: 2.102

8.  Minimal invasive surgery in treatment of liver metastases from colorectal carcinomas: case studies and survival rates.

Authors:  Domenico Loffredo; Alberto Marvaso; Sandro Ceraso; Nicola Cinelli; Aldo Rocca; Mario Vitale; Michele Rossi; Eugenio Genovese; Bruno Amato; Mariapia Cinelli
Journal:  BMC Surg       Date:  2013-10-08       Impact factor: 2.102

9.  Antiarrhythmic drug usage and prostate cancer: a population-based cohort study.

Authors:  Li-Ting Kao; Chung-Chien Huang; Herng-Ching Lin; Chao-Yuan Huang
Journal:  Asian J Androl       Date:  2018 Jan-Feb       Impact factor: 3.285

10.  Exploration of the molecular mechanism of prostate cancer based on mRNA and miRNA expression profiles.

Authors:  Xing Zhang; YuYan Sun; Peng Wang; Changfu Yang; Shengwei Li
Journal:  Onco Targets Ther       Date:  2017-06-29       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.